Breaking News

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
AMRS Amyris $4.01 -0.04 (-0.99%) 17:07 01/08/19 01/08 17:07 01/08/19 17:07 Syndicate	Breaking Syndicate news story on Amyris » Amyris files to sell… Amyris files to sell 19.54M shares of common stock for holders 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AMRS Amyris $3.42 -0.115 (-3.25%) 12:41 12/31/18 12/31 12:41 12/31/18 12:41 Recommendations	Amyris analyst commentary at H.C. Wainwright » Amyris news today a… Amyris news today a 'significant near-term milestone,' says H.C. Wainwright. H.C. Wainwright analyst Amit Dayal maintains a Buy rating on Amyris with an $11 price target after the company entered into a long-term agreement with Xinfu for an upfront payment of $50M and an additional long-term annual share upside based on an existing nutritional product royalty arrangement. Amyris is capitalizing on its relationship with Xinfu to monetize a portion of the long-term royalty opportunity upfront, which should lower quarterly volatility from this "high-margin" revenue stream while continuing to benefit from future royalty payments, Dayal tells investors in a research note. He thinks today's news should be viewed as a "timely delivery of a significant near-term milestone by the management team." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AMRS Amyris $3.54 0.075 (2.17%) 08:36 12/31/18 12/31 08:36 12/31/18 08:36 Hot Stocks	Amyris signs agreement with Xinfu for nutritional product royalty » Amyris announced that it… Amyris announced that it has signed a long-term agreement with Xinfu of China for a significant initial payment and a long-term minimum annual share of an existing nutritional product royalty arrangement. This agreement enables Amyris to monetize a portion of the long-term royalty opportunity for this product upfront to manage volatility in a high-margin revenue stream. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a month ago
AMRS Amyris $4.35 -0.06 (-1.36%) 08:41 12/12/18 12/12 08:41 12/12/18 08:41 Hot Stocks	Amyris receives GRAS notification from FDA for zero calorie sweetener » Amyris announced that it… Amyris announced that it has received a successful GRAS notification from the FDA for its zero calorie sweetener. With this notification, the FDA has accepted the unanimous conclusion of a panel of food-safety experts, the company announced on August 30, that Amyris's zero calorie sweetener made from sugarcane is safe for use as a sweetener. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AMRS Amyris $4.33 0.16 (3.84%) 08:40 12/10/18 12/10 08:40 12/10/18 08:40 Hot Stocks	Amyris expands production agreement with ADL Bionatur » Amyris announced that it… Amyris announced that it has executed an expanded agreement for its existing production contract with ADL Bionatur Solutions, through its fermentation division ADL Biopharma. ADL Bionatur provides cost effective, contract manufacturing capabilities. This marks the second expansion of an agreement the parties executed. This expanded agreement supports confidence in ADL Bionatur Solutions by Amyris. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

AMRS Amyris $4.54 0.37 (8.87%) 11:38 12/07/18 12/07 11:38 12/07/18 11:38 Recommendations	Amyris analyst commentary at H.C. Wainwright » Amyris financing removes… Amyris financing removes 'important overhang,' says H.C. Wainwright. H.C. Wainwright analyst Amit Dayal reiterated a Buy rating and $11 price target on Amyris, noting that the company announced it has entered into definitive agreements for the sale of $60M of unsecured convertible senior notes, in a private placement with two investors. Dayal said this financing removes an "important overhang" for the company, and believes that Amyris is now positioned to focus on execution during 2019. The analyst added that he is looking forward to more information from the company during the last three weeks of this year, including the announcement of a Chinese licensing agreement. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AMRS Amyris $4.96 0.15 (3.12%) 07:25 12/03/18 12/03 07:25 12/03/18 07:25 Hot Stocks	Amyris announces exclusive partnership with Camil Alimentos » Amyris has announced a… Amyris has announced a new partnership with Camil Alimentos to meet growing consumer demand for zero calorie natural sweeteners. The agreement, which provides exclusivity between Camil Alimentos and Amyris in Latin America, consists of the development of an innovative option of a natural sweetener, zero calorie and extracted from sugarcane. The partnership which will begin in Brazil, a country in which the company leads the sugar category and offers the most complete portfolio of the segment, will be the first market to receive the innovation. Camil Alimentos has a broad market reach through 300,000 points of sale including retail, cafes and restaurants. The company is also the owner of Brazil's number one sugar brand Uniao. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AMRS Amyris $4.81 0.05 (1.05%) 09:02 11/30/18 11/30 09:02 11/30/18 09:02 Hot Stocks	Amyris partners with Givaudan for tabletop application for its sweetener » Amyris announced the… Amyris announced the introduction of a new tabletop sweetener application developed in collaboration with Givaudan. Research shows a rise in obesity and diabetes around the world, yet people still crave the sweetness of sugar. Amyris has developed a sweetener that is naturally sourced from sugarcane and has zero calories. The tabletop sweetener application, available initially in Brazil and expected to roll out in other markets in the near future. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AMRS Amyris $5.90 0.04 (0.68%) 07:34 11/14/18 11/14 07:34 11/14/18 07:34 Recommendations	Amyris analyst commentary at H.C. Wainwright » Amyris price target… Amyris price target lowered to $11 from $15 at H.C. Wainwright. H.C. Wainwright analyst Amit Dayal lowered his price target for Amyris to $11 to reflect a more conservative stance on forward projections, including removing around $40M of anticipated annual Vitamin E royalty revenues, following the company's revenue miss in Q3. The analyst, however, keeps a Buy rating on the shares. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
PETQ PetIQ $31.27 -1.77 (-5.36%) , MTSI Macom $15.17 0.28 (1.88%) … 19:01 11/13/18 11/13 19:01 11/13/18 19:01 Hot Stocks	Fly Intel: After Hours Movers » UP AFTER EARNINGS: PetIQ… UP AFTER EARNINGS: PetIQ (PETQ) up 7.1%... MACOM Technology Solutions (MTSI) up 7.0%... SVMK Inc. (SVMK) up 6.3%... Resideo Technologies (REZI) up 3.4%... Laureate Education (LAUR) up 2.1%... Varex Imaging Corp (VREX) up 1.2%... SVB Financial (SIVB) up 1.0%. ALSO HIGHER: Cloud Peak Energy (CLD) up 7.5% after announcing review of strategic alternatives... Etsy (ETSY) up 2.3% after being initiated with a Buy at BTIG... 3M (MMM) up 1.8% after announcing new $10B stock buyback... Eagle Bancorp (EGBN) up 1.4% after announcement it will enter S&P SmallCap 600 index... Golden Entertaintment (GDEN) up 1.3% after announcing CFO stock purchase... Akebia Therapeutics (AKBA) up 0.9% after board recommended vote in favor of Keryx merger. DOWN AFTER EARNINGS: Amirys (AMRS) down 31.9%... Quest Resource Holding Corp (QRHC) down 7.1%... Switch (SWCH) down 6.1%... Wix.com (WIX) down 4.7%... Tilray (TLRY) down 2.2%... Blue Apron (APRN) down 1.6%. ALSO LOWER: Resonant (RESN) down 11.8% after equity offering... CareDX (CDNA) down 2.9% after equity offering... Ladder Capital (LADR) down 1.5% after equity offering... Consolidated Edison (ED) down 0.8% after equity offering. PETQ PetIQ $31.27 -1.77 (-5.36%) MTSI Macom $15.17 0.28 (1.88%) SVMK SurveyMonkey $11.33 -0.185 (-1.61%) REZI Resideo $21.28 -0.06 (-0.28%) LAUR Laureate Education $15.53 -0.41 (-2.57%) VREX Varex Imaging $26.11 -0.65 (-2.43%) SIVB SVB Financial $242.68 1.84 (0.76%) CLD Cloud Peak $1.32 -0.12 (-8.33%) ETSY Etsy $47.31 -3.33 (-6.58%) MMM 3M $198.40 1.31 (0.66%) EGBN Eagle Bancorp $49.19 0.48 (0.99%) GDEN Golden Entertainment $14.32 -0.46 (-3.11%) AKBA Akebia $7.76 0.04 (0.52%) AMRS Amyris $5.90 0.04 (0.68%) QRHC Quest Resource $2.23 -0.01 (-0.45%) SWCH Switch $9.27 -0.075 (-0.80%) WIX Wix.com $91.30 2.83 (3.20%) TLRY Tilray $111.25 -1.95 (-1.72%) APRN Blue Apron $1.22 -0.03 (-2.40%) RESN Resonant $2.88 -0.03 (-1.03%) CDNA CareDx $25.49 -2.01 (-7.31%) LADR Ladder Capital $17.58 -0.03 (-0.17%) ED Consolidated Edison $79.14 0.48 (0.61%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	13 Nov 13 Nov 13 Nov 13 Nov 13 Nov 13 Nov 13 Nov 13 Nov 13 Nov 13 Nov 13 Nov 13 Nov 13 Nov 13 Nov 14 Nov 14 Nov 14 Nov 15 Nov 15 Nov 27 Nov 27 Nov 28 Nov 04 Dec 11 Dec 14 Nov 14 Nov 15 Nov 16 Nov

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial